- Home
- NRBO
as 07-26-2024 4:00pm EST
NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 45.4M | IPO Year: | N/A |
| Target Price: | $10.00 | AVG Volume (30 days): | 43.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.22 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.90 - $6.75 | Next Earning Date: | 08-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of NeuroBo Pharmaceuticals Inc. (NRBO)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| DONG-A ST CO., LTD | NRBO | 10% Owner | Jun 23 '24 | Buy | $3.13 | 2,544,530 | $7,964,378.90 | 5,348,229 | SEC Form 4 |
Latest NeuroBo Pharmaceuticals Inc. News
NRBO Breaking Stock News: Dive into NRBO Ticker-Specific Updates for Smart Investing
GlobeNewswire
10 days ago
Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now
PR Newswire
16 days ago
NeuroBo Pharmaceuticals to Present at the Emerging Growth Conference in July
Zacks Small Cap Research
25 days ago
NRBO: DA-1726 Shows Superiority to Survodutide in Pre-Clinical Models…
Clinical Trials Arena
a month ago
NeuroBo doses first subject in Part 2 of Phase I obesity treatment trial
PR Newswire
a month ago
NeuroBo Pharmaceuticals Doses First Patient in the MAD Part 2 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
MT Newswires
a month ago
NeuroBo Pharmaceuticals Raises $20 Million from Share Placement
PR Newswire
a month ago
NeuroBo Pharmaceuticals Announces the Closing of up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
MT Newswires
a month ago
NeuroBo Pharmaceuticals Announces Private Placement, Registered Direct Offering
Compare NRBO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NRBO NeuroBo Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.